Inverse agonist properties of antipsychotic agents at cloned, human (h) serotonin (5-HT)1B and h5-HT1D receptors

被引:37
作者
Audinot, V [1 ]
Newman-Tancredi, A [1 ]
Cussac, D [1 ]
Millan, MJ [1 ]
机构
[1] Inst Rech Servier, Dept Psychopharmacol, Dept Mol & Cellular Pharmacol, F-78290 Croissy Sur Seine, Paris, France
关键词
5-HT1B; 5-HT1D; schizophrenia; 5-5-schizophrenia; antipsychotic; clozapine; inverse agonist;
D O I
10.1016/S0893-133X(01)00237-8
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The actions of diverse antipsychotics at cloned h5-HT1B and h5-HT1D receptors were examined employing [H-3]-GR125,743 and [S-35]-GTP gammaS for determination of affinities and efficacies, respectively. Compared with hD(2) receptors, haloperidol, chlorpromazine and olanzapine showed markedly (> 100-fold) lower affinity for h5-HT1D and h5-HT1B receptors at which they expressed inverse agonist properties. Clozapine, risperidone and ocaperidone likewise behaved as inverse agonists at h5-HT1B and h5-HT1D receptors but their affinities were only similar to 10-fold lower than at hD2 receptors. Moreover, ziprasidone, S16924 and ORG5222 interacted at h5-HT1B and h5-HT1D receptors with affinities similar to hD(2) sites. While S16924 and ORG5222 were inverse agonists at h5-HT1B anti h5-HT1D sites, ziprasidone was an inverse agonist at h5-HT1D receptors yet a partial agonist tit h5-HT1B receptors. These actions of antipsychotics were abolished by the selective, neutral antagonist, S18127. In conclusion, with the exception cf ziprasidone, till antipsychotics were inverse agonists at h5-HT1B; and h5-HT1D receptors, although they differed markedly in their potency tit these sites as compared to hD(2) receptors. (C) 2001 American College of Neuropsychopharmacology. Published by Elsevier Science Inc.
引用
收藏
页码:410 / 422
页数:13
相关论文
共 101 条
[1]  
ADHAM N, 1993, MOL PHARMACOL, V43, P427
[2]   Characterization of 5-HT1A receptor-mediated [35S]GTPγS binding in rat hippocampal membranes [J].
Alper, RH ;
Nelson, DL .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 343 (2-3) :303-312
[3]   Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence [J].
Arnt, J ;
Skarsfeldt, T .
NEUROPSYCHOPHARMACOLOGY, 1998, 18 (02) :63-101
[4]   Binding profile of the novel 5-HT1B/1D receptor antagonist, [H-3]GR 125,743, in guinea-pig brain: A comparison with [H-3]5-carboxamidotryptamine [J].
Audinot, V ;
Lochon, S ;
NewmanTancredi, A ;
Lavielle, G ;
Millan, MJ .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 327 (2-3) :247-256
[5]   Constitutive activity at serotonin 5-HT1D receptors:: detection by homologous GTPγS versus [35S]-GTPγS binding isotherms [J].
Audinot, V ;
Newman-Tancredi, A ;
Millan, MJ .
NEUROPHARMACOLOGY, 2001, 40 (01) :57-64
[6]   A review of central 5-HT receptors and their function [J].
Barnes, NM ;
Sharp, T .
NEUROPHARMACOLOGY, 1999, 38 (08) :1083-1152
[7]   Absence of cocaine-induced place conditioning in serotonin 1B receptor knock-out mice [J].
Belzung, C ;
Scearce-Levie, K ;
Barreau, S ;
Hen, R .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2000, 66 (01) :221-225
[8]   MOLECULAR-BIOLOGY OF 5-HT RECEPTORS [J].
BOESS, FG ;
MARTIN, IL .
NEUROPHARMACOLOGY, 1994, 33 (3-4) :275-317
[9]   Humanization of mouse 5-hydroxytryptamine1B receptor gene by homologous recombination:: In vitro and in vivo characterization [J].
Bonaventure, P ;
Umans, L ;
Bakker, MHM ;
Cras, P ;
Langlois, X ;
Luyten, WHML ;
Megens, AAHP ;
Serneels, L ;
Van Leuven, F ;
Leysen, JE .
MOLECULAR PHARMACOLOGY, 1999, 56 (01) :54-67
[10]  
Bonaventure P, 1997, RECEPTOR CHANNEL, V5, P225